RECENT studies have suggested that the development of blood eosinophilia during insulin coma therapy may have prognostic significance.1 These observations have for the most part been concerned with the immediate clinical response to insulin coma therapy. In order to evaluate the continued benefit of therapy, we have done a three-year follow-up study of 11 patients whose blood eosinophile levels were recorded as part of a pilot study of various metabolic changes in a consecutive series of patients receiving insulin coma therapy at our hospital between January and September, 1950. Changes in blood cholesterol and blood cholesterol esters have been reported elsewhere by Goodman and Kanter.2
In our hospital patients are selected for insulin coma therapy by a medical board consisting of the chief, acute-intensive treatment service; the ward physician, and the resident in psychiatry. Prior to presentation the patients have a thorough work-up, which includes psychiatric evaluation,
FREEMAN RV, JONES TE, PALMER JJ. THREE-YEAR FOLLOW-UP OF PATIENTS DEVELOPING EOSINOPHILIA DURING INSULIN COMA THERAPY. AMA Arch NeurPsych. 1954;71(4):501–510. doi:10.1001/archneurpsyc.1954.02320400097010
Customize your JAMA Network experience by selecting one or more topics from the list below.